Patients who received oral paclitaxel with encequidar had lower rates of neuropathy, but higher rates of neutropenia, anemia, and gastrointestinal adverse events.
Image-guided core-needle biopsy did not improve the predictive value of trimodality imaging after neoadjuvant therapy for patients with operable breast cancer.
A multicenter pooled analysis found that residual cancer burden index after neoadjuvant therapy was prognostic in the long-term across 4 breast cancer subtypes.
Compared to historical controls, adjuvant paclitaxel and trastuzumab seems to provide the same benefit for patients with low-risk, HER2-positive early breast cancer.
Researchers warn that pathologists may be assigning the wrong immune cell score with PD-L1 assays to patients, leading to inappropriate treatment recommendations.
Margetuximab plus chemotherapy continues to improve outcomes in patients with HER2-positive metastatic breast cancer, particularly among CD16A-F carriers.
Patients at high risk of recurrence had an invasive disease-free survival benefit from pertuzumab in the long term, but the survival benefit is unclear.
Adding tucatinib to capecitabine and trastuzumab improved survival for patients with metastatic HER2-positive breast cancer, including those with brain metastases.
Talks from the meeting will offer insights on the prevention and diagnosis of disease, and will also compare novel therapeutic interventions with older standards of care.